Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Development of natural products for anti-PD-1/PD-L1 immunotherapy against cancer
MyongHak Ri, Juan Ma, Xuejun Jin
Journal of Ethnopharmacology (2021) Vol. 281, pp. 114370-114370
Closed Access | Times Cited: 33

Showing 1-25 of 33 citing articles:

Tumor immune escape: extracellular vesicles roles and therapeutics application
Mahdi Ahmadi, Reza Abbasi, Jafar Rezaie
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 21
The opportunities and challenges of using PD-1/PD-L1 inhibitors for leukemia treatment
Mengdan Xu, Shenglong Li
Cancer Letters (2024) Vol. 593, pp. 216969-216969
Closed Access | Times Cited: 9
Natural products and their derivatives as immune check point inhibitors: Targeting cytokine/chemokine signalling in cancer
Meenakshi Gupta, Kumari Chandan, Maryam Sarwat
Seminars in Cancer Biology (2022) Vol. 86, pp. 214-232
Closed Access | Times Cited: 32
Uncovering the colorectal cancer immunotherapeutic potential: Evening primrose (Oenothera biennis) root extract and its active compound oenothein B targeting the PD-1/PD-L1 blockade
Eun‐Ji Lee, Young Soo Kim, Ji Hye Kim, et al.
Phytomedicine (2024) Vol. 125, pp. 155370-155370
Open Access | Times Cited: 5
Diterpenes: Nature’s Hidden Gems of Immunomodulation
Jonas S. Almeida, André Correa de Oliveira, Carlos Eduardo de Castro Alves, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 5, pp. 2250-2250
Open Access
Regulatory mechanisms of natural compounds from traditional Chinese herbal medicines on the microglial response in ischemic stroke
MyongHak Ri, Yue Xing, Hong Xiang Zuo, et al.
Phytomedicine (2023) Vol. 116, pp. 154889-154889
Closed Access | Times Cited: 13
The current status and future of PD-L1 in liver cancer
Liyuan Hao, Shenghao Li, Jiali Deng, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 11
Immunoadjuvants for cancer immunotherapy
Ana Maria Carmona‐Ribeiro
Elsevier eBooks (2024), pp. 1-36
Closed Access | Times Cited: 3
Nature’s Arsenal: Harnessing the Capacity of Phytochemicals to Enhance Immune Checkpoint Inhibitor Therapy of Cancers: An Especial Attention to Brain Malignancies
Amir R. Afshari, Mehdi Sanati, Seyed Sajad Ahmadi, et al.
Cancer Letters (2024) Vol. 593, pp. 216955-216955
Closed Access | Times Cited: 3
The Role of Tumor Microenvironment in Invasion and Metastasis of Esophageal Squamous Cell Carcinoma
Shuyue Zheng, Beilei Liu, Xin‐Yuan Guan
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 17
Nano-formulated delivery of active ingredients from traditional Chinese herbal medicines for cancer immunotherapy
Qi Shang, Wandong Liu, Faith Leslie, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 14, Iss. 4, pp. 1525-1541
Open Access | Times Cited: 9
Advances in plant-derived natural products for antitumor immunotherapy
Yi‐Hsin Yang, Qinying Liu, Xianai Shi, et al.
Archives of Pharmacal Research (2021) Vol. 44, Iss. 11, pp. 987-1011
Closed Access | Times Cited: 22
Development of novel peptide-based radiotracers for detecting PD-L1 expression and guiding cancer immunotherapy
Shiyu Zhu, Beibei Liang, Yuxuan Zhou, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2023) Vol. 51, Iss. 3, pp. 625-640
Closed Access | Times Cited: 7
A phenolic based tumor-permeated nano-framework for immunogenic cell death induction combined with PD-L1 immune checkpoint blockade
Xiaoyan Sun, Jiulong Zhang, Jingya Xiu, et al.
Biomaterials Science (2022) Vol. 10, Iss. 14, pp. 3808-3822
Closed Access | Times Cited: 10
Breaking the Bottleneck in Anticancer Drug Development: Efficient Utilization of Synthetic Biology
Haibo Wang, Yu He, Meiling Jian, et al.
Molecules (2022) Vol. 27, Iss. 21, pp. 7480-7480
Open Access | Times Cited: 10
In silico assessment of a natural small molecule as an inhibitor of programmed death ligand 1 for cancer immunotherapy: a computational approach
Nahed S. Alharthi, Maher S. Alwethaynani, Abdulfattah Yahya M. Alhazmi, et al.
Journal of Biomolecular Structure and Dynamics (2024), pp. 1-21
Closed Access | Times Cited: 1
Computational Investigations on the Natural Small Molecule as an Inhibitor of Programmed Death Ligand 1 for Cancer Immunotherapy
Geethu S. Kumar, Mahmoud Moustafa, Amaresh Kumar Sahoo, et al.
Life (2022) Vol. 12, Iss. 5, pp. 659-659
Open Access | Times Cited: 7
Panaxadiol inhibits IL-1β secretion by suppressing zinc finger protein 91-regulated activation of non-canonical caspase-8 inflammasome and MAPKs in macrophages
Jing Ying Wang, Yue Xing, Ming Yue Li, et al.
Journal of Ethnopharmacology (2021) Vol. 283, pp. 114715-114715
Closed Access | Times Cited: 10
Augmented Antitumor Effect of Unripe Rubus coreanus Miquel Combined with Oxaliplatin in a Humanized PD-1/PD-L1 Knock-In Colorectal Cancer Mouse Model
Eun‐Ji Lee, Ju-Hye Yang, Jang-Gi Choi, et al.
Cells (2022) Vol. 11, Iss. 18, pp. 2876-2876
Open Access | Times Cited: 5
Berberine: a comprehensive Approach to combat human maladies
Zarina Mushtaq, Muhammad Imran, Farhan Saeed, et al.
International Journal of Food Properties (2023) Vol. 26, Iss. 1, pp. 787-807
Open Access | Times Cited: 2
Look Into My Onco-forest - Review of Plant Natural Products with Anticancer Activity
Izabela Michalak, Mirosława Püsküllüoğlu
Current Topics in Medicinal Chemistry (2022) Vol. 22, Iss. 11, pp. 922-938
Closed Access | Times Cited: 4
FOXO3-dependent suppression of PD-L1 promotes anticancer immune responses via activation of natural killer cells.
Young‐Min Chung, Wen-Bin Tsai, Pragya P Khan, et al.
PubMed (2022) Vol. 12, Iss. 3, pp. 1241-1263
Closed Access | Times Cited: 4
Research progress of PD‐L1 non‐glycosylation in cancer immunotherapy
Pu Cao, Xiaoyan Yang, Daquan Liu, et al.
Scandinavian Journal of Immunology (2022) Vol. 96, Iss. 4
Closed Access | Times Cited: 4
Molecular docking study of britannin binding to PD-L1 and related anticancer pseudoguaianolide sesquiterpene lactones
Gérard Vergoten, Christian Bailly
Journal of Receptors and Signal Transduction (2021) Vol. 42, Iss. 5, pp. 454-461
Closed Access | Times Cited: 5
Neogambogic acid enhances anti-PD-1 immunotherapy efficacy by attenuating suppressive function of MDSCs in pancreatic cancer
Jing Xun, Xiaolin Jiang, Bin Liu, et al.
International Immunopharmacology (2024) Vol. 139, pp. 112696-112696
Closed Access
Page 1 - Next Page

Scroll to top